CML概述与格尼可经验分享.pptVIP

  • 4
  • 0
  • 约1.05万字
  • 约 45页
  • 2018-12-28 发布于浙江
  • 举报
这张图表上面的线条越粗显示该药对该基因位点的作用越强 GIST,氟马替尼 * 152?Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056) At 5 years, dasatinib 100 mg once daily has demonstrated superior outcome compared to imatinib 400 mg once daily as initial therapy for CML. This is manifested by a faster time to cytogenetic and molecular responses, with more pts achieving BCR-ABL ≤10% at 3 months, sustained higher cumulative rates of response, and a lower rate of transformation. The 5-year rates of PFS and OS were equal in bot

文档评论(0)

1亿VIP精品文档

相关文档